Ex­sci­en­tia ends can­cer study as it fo­cus­es on oth­er tri­als of AI-dri­ven drug can­di­dates

AI drug dis­cov­ery and de­vel­op­ment com­pa­ny Ex­sci­en­tia is stop­ping a sol­id tu­mor tri­al as it re­fo­cus­es its in­ter­nal pipeline amid plans to ink an­oth­er part­ner­ship …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER